|Articles|August 20, 2021

Rheumatoid Arthritis Quiz: 2021 Highlights

Test your knowledge with our Rheumatoid Arthritis: 2021 Highlights quiz!

Is the following statement True or False?

Biologics are generally more effective than conventional first line treatment for early RA in treatment-naïve patients.

Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to Rheumatology Live today.

Related to this article

October 2nd, 2026

Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.

September 23rd, 2026

The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.

September 4th, 2026

August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.

August 6th, 2026

In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.

$AB-101 + Rituximab Shows Deep Responses in Refractory RA, SjD, SSc$

July 27th, 2026

A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.